Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Core Viewpoint - Arvinas, Inc. has made significant progress in 2025, including the submission of its first new drug application, which could lead to the first FDA approval of a PROTAC degrader, while focusing on maximizing opportunities in its pipeline with ongoing clinical trials in oncology and neurology [2][6]. Financial Results - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $685.4 million, down from $1,039.4 million at the end of 2024, primarily due to operational cash usage of $261.0 million and share repurchases of $91.9 million [15]. - Revenue for the year was $262.6 million, slightly down from $263.4 million in 2024, mainly due to a decrease in revenue from the Novartis License Agreement and the Pfizer Research Collaboration Agreement [21][22]. Research and Development Highlights - The company has four ongoing clinical trials, including ARV-102 for Parkinson's disease, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for B-cell lymphomas, and ARV-027 for spinal and bulbar muscular atrophy [6][24][25][26][27]. - ARV-806 demonstrated over 25-fold greater potency in reducing cancer cell proliferation and over 40-fold higher potency in degrading KRAS G12D protein compared to other clinical-stage G12D degraders [12]. - ARV-393 showed significant tumor growth inhibition when combined with glofitamab, indicating potential for a chemotherapy-free treatment approach in diffuse large B-cell lymphoma [12]. Corporate Developments - Randy Teel, Ph.D., has been appointed as President and CEO, succeeding John Houston, who will remain on the Board [7]. - The company plans to host a conference call to discuss its financial results and corporate updates [23]. Upcoming Milestones - Anticipated milestones include data readouts from ARV-102, ARV-806, and ARV-393, with plans to initiate several Phase 1 clinical trials in 2026 [6][16][30]. - The FDA has set a Prescription Drug User Fee Act action date of June 5, 2026, for vepdegestrant, which has received Fast Track designation [30]. Pipeline Overview - ARV-102 targets LRRK2 for neurodegenerative disorders, ARV-806 targets KRAS G12D for various cancers, ARV-393 targets BCL6 for non-Hodgkin lymphoma, ARV-027 targets polyQ-AR for spinal and bulbar muscular atrophy, and vepdegestrant targets the estrogen receptor for breast cancer [32].